ASH 2019 | Donor-derived allogeneic CAR-T for B-ALL post-transplant
Second generation CD19 CAR T-cells show exceptional efficacy in acute B-cell acute lymphoblastic leukemia (B-ALL), but it can be challenging to generate products from lymphopenic patients post allogeneic stem cell transplant (allo-SCT). Claire Roddie, MD, PhD, University College London, London, United Kingdom, discusses the rationale and results from the CARD study (NCT02893189). This phase I trial proposed the use of matched donor T-cells to overcome the challenges caused by patient lymphopenia. Dr Roddie reveals that this approach could come with a heightened risk of graft-versus-host disease (GvHD). However, results show that donor-derived matched allogeneic anti-CD19 CAR T-cells deliver excellent early remission rates in the absence of severe CAR-associated toxicity or GvHD. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Get great new content delivered to your inboxSign up